1
|
Li X, Wang H, Wang H, Bullert AJ, Cui JY, Wang K, Lehmler HJ. Germ-free status but not subacute polychlorinated biphenyl (PCB) exposure altered hepatic phosphatidylcholine and ether-phosphatidylcholine levels in mice. Toxicology 2024; 504:153790. [PMID: 38552894 DOI: 10.1016/j.tox.2024.153790] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2024] [Revised: 03/19/2024] [Accepted: 03/26/2024] [Indexed: 04/06/2024]
Abstract
Polychlorinated biphenyls (PCBs) are persistent organic pollutants that pose a current ecosystem and human health concern. PCB exposure impacts the gut microbiome in animal models, suggesting a mechanistic link between PCB exposure and adverse health outcomes. The presence and absence of the microbiome and exposure to PCBs independently affect the lipid composition in the liver, which in turn affects the PCB disposition in target tissues, such as the liver. Here, we investigated microbiome × subacute PCB effects on the hepatic lipid composition of conventional and germ-free female mice exposed to 0, 6, or 30 mg/kg body weight of an environmental PCB mixture in sterile corn oil once daily for 3 consecutive days. Hepatic triacylglyceride and polar lipid levels were quantified using mass spectrometric methods following the subacute PCB exposure. The lipidomic analysis revealed no PCB effect on the hepatic levels. No microbiome effect was observed on levels of triacylglyceride and most polar lipid classes. The total hepatic levels of phosphatidylcholine (PC) and ether-phosphatidylcholine (ePC) lipids were lower in germ-free mice than the conventional mice from the same exposure group. Moreover, levels of several unsaturated PCs, such as PC(36:5) and PC(42:10), and ePCs, such as ePC(36:2) and ePC(4:2), were lower in germ-free than conventional female mice. Based on a KEGG pathway meta-analysis of RNA sequencing data, the ether lipid metabolism pathway is altered in the germ-free mouse liver. In contrast to the liver, extractable lipid levels, determined gravimetrically, differed in several tissues from naïve conventional vs. germ-free mice. Overall, microbiome × subacute PCB exposure effects on hepatic lipid composition are unlikely to affect PCB distribution into the mouse liver. Further studies are needed to assess how the different extractable lipid levels in other tissues alter PCB distribution in conventional vs. germ-free mice.
Collapse
Affiliation(s)
- Xueshu Li
- Department of Occupational and Environmental Health, University of Iowa, Iowa City, IA 52242, USA
| | - Hui Wang
- Department of Occupational and Environmental Health, University of Iowa, Iowa City, IA 52242, USA
| | - Hui Wang
- Department of Occupational and Environmental Health, University of Iowa, Iowa City, IA 52242, USA
| | - Amanda J Bullert
- Department of Occupational and Environmental Health, University of Iowa, Iowa City, IA 52242, USA; Interdisciplinary Graduate Program in Neuroscience, University of Iowa, University of Iowa, Iowa City, IA 52242, USA
| | - Julia Yue Cui
- Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, WA 98105, USA
| | - Kai Wang
- Department of Biostatistics, University of Iowa, Iowa City, IA 52242, USA
| | - Hans-Joachim Lehmler
- Department of Occupational and Environmental Health, University of Iowa, Iowa City, IA 52242, USA; Interdisciplinary Graduate Program in Neuroscience, University of Iowa, University of Iowa, Iowa City, IA 52242, USA.
| |
Collapse
|
2
|
Nie MT, Wang PQ, Shi PM, Hong XL, Zhang X, Xiang B, Zhang M, Xie WF. Rifaximin treatment shapes a unique metagenome-metabolism network in patients with decompensated cirrhosis. J Gastroenterol Hepatol 2024; 39:762-771. [PMID: 38233085 DOI: 10.1111/jgh.16484] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/07/2023] [Revised: 12/04/2023] [Accepted: 12/20/2023] [Indexed: 01/19/2024]
Abstract
BACKGROUND Patients with decompensated cirrhosis face poor prognosis and increased mortality risk. Rifaximin, a non-absorbable antibiotic, has been shown to have beneficial effects in preventing complications and improving survival in these patients. However, the underlying mechanisms of rifaximin's effects remain unclear. METHODS We obtained fecal samples from decompensated cirrhotic patients undergoing rifaximin treatment and controls, both at baseline and after 6 months of treatment. Shotgun metagenome sequencing profiled the gut microbiome, and untargeted metabolomics analyzed fecal metabolites. Linear discriminant and partial least squares discrimination analyses were used to identify differing species and metabolites between rifaximin-treated patients and controls. RESULTS Forty-two patients were enrolled and divided into two groups (26 patients in the rifaximin group and 16 patients in the control group). The gut microbiome's beta diversity changed in the rifaximin group but remained unaffected in the control group. We observed 44 species with reduced abundance in the rifaximin group, including Streptococcus_salivarius, Streptococcus_vestibularis, Haemophilus_parainfluenzae, etc. compared to only four in the control group. Additionally, six species were enriched in the rifaximin group, including Eubacterium_sp._CAG:248, Prevotella_sp._CAG:604, etc., and 14 in the control group. Furthermore, rifaximin modulated different microbial functions compared to the control. Seventeen microbiome-related metabolites were altered due to rifaximin, while six were altered in the control group. CONCLUSION Our study revealed distinct microbiome-metabolite networks regulated by rifaximin intervention in patients with decompensated cirrhosis. These findings suggest that targeting these specific metabolites or related bacteria might be a potential therapeutic strategy for decompensated cirrhosis.
Collapse
Affiliation(s)
- Mei-Tong Nie
- Department of Gastroenterology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China
| | - Pei-Qin Wang
- Department of Gastroenterology, Changzheng Hospital, Naval Medical University, Shanghai, China
| | - Pei-Mei Shi
- Department of Gastroenterology, Changzheng Hospital, Naval Medical University, Shanghai, China
| | - Xia-Lu Hong
- Department of Gastroenterology, Changzheng Hospital, Naval Medical University, Shanghai, China
| | - Xin Zhang
- Department of Gastroenterology, Changzheng Hospital, Naval Medical University, Shanghai, China
| | - Baoyu Xiang
- State Key Laboratory of Microbial Metabolism, Joint International Research Laboratory of Metabolic and Developmental Sciences, and School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China
| | - Menghui Zhang
- State Key Laboratory of Microbial Metabolism, Joint International Research Laboratory of Metabolic and Developmental Sciences, and School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China
| | - Wei-Fen Xie
- Department of Gastroenterology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China
- Department of Gastroenterology, Changzheng Hospital, Naval Medical University, Shanghai, China
| |
Collapse
|
3
|
Oh KK, Choi I, Gupta H, Raja G, Sharma SP, Won SM, Jeong JJ, Lee SB, Cha MG, Kwon GH, Jeong MK, Min BH, Hyun JY, Eom JA, Park HJ, Yoon SJ, Choi MR, Kim DJ, Suk KT. New insight into gut microbiota-derived metabolites to enhance liver regeneration via network pharmacology study. ARTIFICIAL CELLS, NANOMEDICINE, AND BIOTECHNOLOGY 2023; 51:1-12. [PMID: 36562095 DOI: 10.1080/21691401.2022.2155661] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
We intended to identify favourable metabolite(s) and pharmacological mechanism(s) of gut microbiota (GM) for liver regeneration (LR) through network pharmacology. We utilized the gutMGene database to obtain metabolites of GM, and targets associated with metabolites as well as LR-related targets were identified using public databases. Furthermore, we performed a molecular docking assay on the active metabolite(s) and target(s) to verify the network pharmacological concept. We mined a total of 208 metabolites in the gutMGene database and selected 668 targets from the SEA (1,256 targets) and STP (947 targets) databases. Finally, 13 targets were identified between 61 targets and the gutMGene database (243 targets). Protein-protein interaction network analysis showed that AKT1 is a hub target correlated with 12 additional targets. In this study, we describe the potential microbe from the microbiota (E. coli), chemokine signalling pathway, AKT1 and myricetin that accelerate LR, providing scientific evidence for further clinical trials.
Collapse
Affiliation(s)
- Ki-Kwang Oh
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Ickwon Choi
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Haripriya Gupta
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Ganesan Raja
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Satya Priya Sharma
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Sung-Min Won
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Jin-Ju Jeong
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Su-Been Lee
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Min-Gi Cha
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Goo-Hyun Kwon
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Min-Kyo Jeong
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Byeong-Hyun Min
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Ji-Ye Hyun
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Jung-A Eom
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Hee-Jin Park
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Sang-Jun Yoon
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Mi-Ran Choi
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Dong Joon Kim
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Ki-Tae Suk
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| |
Collapse
|
4
|
Stojic J, Kukla M, Grgurevic I. The Intestinal Microbiota in the Development of Chronic Liver Disease: Current Status. Diagnostics (Basel) 2023; 13:2960. [PMID: 37761327 PMCID: PMC10528663 DOI: 10.3390/diagnostics13182960] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2023] [Revised: 09/06/2023] [Accepted: 09/11/2023] [Indexed: 09/29/2023] Open
Abstract
Chronic liver disease (CLD) is a significant global health burden, leading to millions of deaths annually. The gut-liver axis plays a pivotal role in this context, allowing the transport of gut-derived products directly to the liver, as well as biological compounds from the liver to the intestine. The gut microbiota plays a significant role in maintaining the health of the digestive system. A change in gut microbiome composition as seen in dysbiosis is associated with immune dysregulation, altered energy and gut hormone regulation, and increased intestinal permeability, contributing to inflammatory mechanisms and damage to the liver, irrespective of the underlying etiology of CLD. The aim of this review is to present the current knowledge about the composition of the intestinal microbiome in healthy individuals and those with CLD, including the factors that affect this composition, the impact of the altered microbiome on the liver, and the mechanisms by which it occurs. Furthermore, this review analyzes the effects of gut microbiome modulation on the course of CLD, by using pharmacotherapy, nutrition, fecal microbiota transplantation, supplements, and probiotics. This review opens avenues for the translation of knowledge about gut-liver interplay into clinical practice as an additional tool to fight CLD and its complications.
Collapse
Affiliation(s)
- Josip Stojic
- Department of Gastroenterology, Hepatology and Clinical Nutrition, University Hospital Dubrava, 10000 Zagreb, Croatia;
| | - Michał Kukla
- Department of Internal Medicine and Geriatrics, Faculty of Medicine, Jagellonian University Medical College, 31-688 Kraków, Poland;
- Department of Endoscopy, University Hospital, 30-688 Kraków, Poland
| | - Ivica Grgurevic
- Department of Gastroenterology, Hepatology and Clinical Nutrition, University Hospital Dubrava, 10000 Zagreb, Croatia;
- School of Medicine, University of Zagreb, 10000 Zagreb, Croatia
- Faculty of Pharmacy and Biochemistry, University of Zagreb, 10000 Zagreb, Croatia
| |
Collapse
|
5
|
Wang Q, Chen CX, Zuo S, Cao K, Li HY. Global research trends on the links between intestinal microbiota and liver diseases: a bibliometric analysis. Am J Transl Res 2023; 15:5364-5372. [PMID: 37692928 PMCID: PMC10492056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2022] [Accepted: 06/21/2023] [Indexed: 09/12/2023]
Abstract
The number of articles on the relationships between the intestinal microbiota and liver diseases has continued to increase. The aim of this study was to assess publications on this topic, identify research hotspots, and predict trends of future research. Articles on this topic published from 2001 to 2021 were obtained from the Web of Science Core Collection. Bibliometric analysis and visualization were performed to identify research hotspots and trends with the use of the online bibliometric analysis platform, VOSviewer, and CiteSpace. In total, 4415 articles were included for bibliometric analysis. The annual output of research on this topic gradually increased over the past 21 years. China contributed the most publications (1254), while the United States was the core (centrality = 0.35) of the country-cooperation network and Schnabl B published the most articles (n = 80). High-frequency keywords included "gut microbiota", "inflammation", "obesity", "insulin resistance", "disease", "fatty liver disease", "metabolism", and "probiotics". The keywords that have burst in recent years include "intestinal microbiota", "dysbiosis", and "gut-liver axis". The relationships between dysbiosis of the intestinal microbiota and liver diseases, such as nonalcoholic fatty liver disease (NAFLD), cirrhosis, and hepatocellular carcinoma (HCC), are current research hotspots. Treatment for NAFLD, nonalcoholic steatohepatitis, cirrhosis, and HCC via regulation of the intestinal microbiota is predicted as a research hotspot in the following years, especially immunotherapy for HCC. These findings should prove helpful to scholars to direct future research on the relationships between the intestinal microbiota and liver diseases.
Collapse
Affiliation(s)
- Qiang Wang
- Department of Hepatobiliary Surgery, The Affiliated Hospital of Guizhou Medical UniversityGuiyang, Guizhou, P. R. China
- School of Clinical Medicine, Guizhou Medical UniversityGuiyang, Guizhou, P. R. China
| | - Cheng-Xin Chen
- Department of Hepatobiliary Surgery, The Affiliated Hospital of Guizhou Medical UniversityGuiyang, Guizhou, P. R. China
- School of Clinical Medicine, Guizhou Medical UniversityGuiyang, Guizhou, P. R. China
| | - Shi Zuo
- Department of Hepatobiliary Surgery, The Affiliated Hospital of Guizhou Medical UniversityGuiyang, Guizhou, P. R. China
| | - Kun Cao
- Department of Hepatobiliary Surgery, The Affiliated Hospital of Guizhou Medical UniversityGuiyang, Guizhou, P. R. China
| | - Hai-Yang Li
- Department of Hepatobiliary Surgery, The Affiliated Hospital of Guizhou Medical UniversityGuiyang, Guizhou, P. R. China
| |
Collapse
|
6
|
Capparelli R, Cuomo P, Gentile A, Iannelli D. Microbiota-Liver Diseases Interactions. Int J Mol Sci 2023; 24:ijms24043883. [PMID: 36835291 PMCID: PMC9959879 DOI: 10.3390/ijms24043883] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2022] [Revised: 02/08/2023] [Accepted: 02/13/2023] [Indexed: 02/17/2023] Open
Abstract
Gut microbiota regulates essential processes of host metabolism and physiology: synthesis of vitamins, digestion of foods non-digestible by the host (such as fibers), and-most important-protects the digestive tract from pathogens. In this study, we focus on the CRISPR/Cas9 technology, which is extensively used to correct multiple diseases, including liver diseases. Then, we discuss the non-alcoholic fatty liver disease (NAFLD), affecting more than 25% of the global population; colorectal cancer (CRC) is second in mortality. We give space to rarely discussed topics, such as pathobionts and multiple mutations. Pathobionts help to understand the origin and complexity of the microbiota. Since several types of cancers have as target the gut, it is vital extending the research of multiple mutations to the type of cancers affecting the gut-liver axis.
Collapse
|
7
|
Cárdenas-Escudero J, Mármol-Rojas C, Escribano Pintor S, Galán-Madruga D, Cáceres JO. Honey polyphenols: regulators of human microbiota and health. Food Funct 2023; 14:602-620. [PMID: 36541681 DOI: 10.1039/d2fo02715a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
A comprehensive review of research over the last decade was conducted to carry out this work. The main objective of this work is to present relevant evidence of the effect of honey intake on the human intestinal microbiota and its relationship with the improvement of various chronic diseases, such as cirrhosis, metabolic syndrome, diabetes, and obesity, among others. Therefore, this work focuses on the health-improving honey dietary supplementation implications associated with specific changes in the human microbiota and their biochemical mechanisms to enhance the proliferation of beneficial microorganisms and the inhibition of pathogenic microorganisms. Consumption of honey polyphenols significantly improves people's health conditions, especially in patients with chronic disease. Hence, honey intake unequivocally constitutes an alternative way to enhance health and could be used to prevent some relevant chronic diseases.
Collapse
Affiliation(s)
- J Cárdenas-Escudero
- Laser Chemistry Research Group, Department of Analytical Chemistry, Faculty of Chemistry, Complutense University of Madrid, Plaza de Ciencias 1, 28040 Madrid, Spain. .,Analytical Chemistry Department, FCNET, Universidad de Panamá, Bella Vista, Manuel E. Batista and José De Fábrega av., Ciudad Universitaria, Estafeta Universitaria, 3366, Panamá 4, Panamá
| | - C Mármol-Rojas
- Laser Chemistry Research Group, Department of Analytical Chemistry, Faculty of Chemistry, Complutense University of Madrid, Plaza de Ciencias 1, 28040 Madrid, Spain.
| | - S Escribano Pintor
- Laser Chemistry Research Group, Department of Analytical Chemistry, Faculty of Chemistry, Complutense University of Madrid, Plaza de Ciencias 1, 28040 Madrid, Spain.
| | - D Galán-Madruga
- National Centre for Environmental Health. Carlos III Health Institute, Ctra. Majadahonda-Pozuelo km 2.2, 28220 Majadahonda, Madrid, Spain
| | - J O Cáceres
- Laser Chemistry Research Group, Department of Analytical Chemistry, Faculty of Chemistry, Complutense University of Madrid, Plaza de Ciencias 1, 28040 Madrid, Spain.
| |
Collapse
|
8
|
Ghanem CI, Manautou JE. Role and Regulation of Hepatobiliary ATP-Binding Cassette Transporters during Chemical-Induced Liver Injury. Drug Metab Dispos 2022; 50:1376-1388. [PMID: 35914951 PMCID: PMC9513844 DOI: 10.1124/dmd.121.000450] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2021] [Accepted: 07/20/2022] [Indexed: 11/22/2022] Open
Abstract
Severity of drug-induced liver injury (DILI) ranges from mild, asymptomatic, and transient elevations in liver function tests to irreversible liver damage, often needing transplantation. Traditionally, DILI is classified mechanistically as high-frequency intrinsic DILI, commonly dose dependent or DILI that rarely occurs and is idiosyncratic in nature. This latter form is not dose dependent and has a pattern of histopathological manifestation that is not always uniform. Currently, a third type of DILI called indirect hepatotoxicity has been described that is associated with the pharmacological action of the drug. Historically, DILI was primarily linked to drug metabolism events; however, the impact of transporter-mediated rates of drug uptake and excretion has gained greater prominence in DILI research. This review provides a comprehensive view of the major findings from studies examining the contribution of hepatic ATP-binding cassette transporters as key contributors to DILI and how changes in their expression and function influence the development, severity, and overall toxicity outcome. SIGNIFICANCE STATEMENT: Drug-induced liver injury (DILI) continues to be a focal point in drug development research. ATP-binding cassette (ABC) transporters have emerged as important determinants of drug detoxification, disposition, and safety. This review article provides a comprehensive analysis of the literature addressing: (a) the role of hepatic ABC transporters in DILI, (b) the influence of genetic mutations in ABC transporters on DILI, and (c) new areas of research emphasis, such as the influence of the gut microbiota and epigenetic regulation, on ABC transporters.
Collapse
Affiliation(s)
- Carolina I Ghanem
- Instituto de Investigaciones Farmacológicas (ININFA-UBA-CONICET) (C.I.G.) and Cátedra de Fisiopatología (C.I.G.), Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Argentina; and Department of Pharmaceutical Sciences, University of Connecticut, Storrs, Connecticut (J.E.M.)
| | - Jose E Manautou
- Instituto de Investigaciones Farmacológicas (ININFA-UBA-CONICET) (C.I.G.) and Cátedra de Fisiopatología (C.I.G.), Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Argentina; and Department of Pharmaceutical Sciences, University of Connecticut, Storrs, Connecticut (J.E.M.)
| |
Collapse
|
9
|
Philips CA, Schnabl B, Bajaj JS. Gut Microbiome and Alcohol-associated Liver Disease. J Clin Exp Hepatol 2022; 12:1349-1359. [PMID: 36157139 PMCID: PMC9499847 DOI: 10.1016/j.jceh.2021.12.016] [Citation(s) in RCA: 14] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/10/2021] [Accepted: 12/28/2021] [Indexed: 02/07/2023] Open
Abstract
Changes in gut microbiota (GM) may be associated with the causation and progression of multiple liver diseases such as metabolic-associated liver disease, alcohol-associated liver disease (ALD), alcohol-associated hepatitis (AH), primary biliary cholangitis, primary sclerosing cholangitis, autoimmune liver disease, and most importantly, complications of cirrhosis and portal hypertension such as hepatic encephalopathy (HE), infection, and hepatocellular carcinoma. ALD includes simple steatosis, steatohepatitis, AH, cirrhosis, and acute-on-chronic liver failure. Alcohol consumption is associated with GM changes even before ALD development, and continued alcohol intake results in progressive dysbiosis and development of clinical events such as AH, infection, and HE. The composition and function of GM, specific changes in bacterial communities, and the functional metabolism of GM are affected in the spectrum of ALD, as revealed using high-throughput sequencing. It was reported in preliminary studies that modulation of disrupted GM improves adverse clinical events and ameliorates disease progression in ALD. In this review, we exhaustively discuss the preclinical and clinical studies on GM in ALD and critically discuss GM modulation and its effects based on various human and animal models of ALD.
Collapse
Key Words
- ACLF
- ACLF, acute on chronic liver failure
- AH, alcohol-associated hepatitis
- ALD
- ALD, alcohol-associated liver disease
- AUD, alcohol use disorder
- FMT
- FMT, fecal microbiota transplantation
- GM, gut microbiota
- HE, hepatic encephalopathy
- IL, interleukin
- MAFLD, metabolic-associated fatty liver disease
- SCFA, short chain fatty acids
- cirrhosis
- microbiome
Collapse
Affiliation(s)
- Cyriac A. Philips
- Department of Clinical and Translational Hepatology and The Monarch Liver Laboratory, The Liver Institute, Center for Excellence in Gastrointestinal Sciences, Rajagiri Hospital, Aluva, Kerala, India
| | - Bernd Schnabl
- Department of Medicine, University of California San Diego, La Jolla, CA, USA
| | - Jasmohan S. Bajaj
- Division of Gastroenterology, Hepatology, and Nutrition, Department of Internal Medicine, Virginia Commonwealth University and Central Virginia Veterans Healthcare System, Richmond, VA, USA
| |
Collapse
|
10
|
Wang L, Dong XL, Qin XM, Li ZY. Investigating the inter-individual variability of Astragali Radix against cisplatin-induced liver injury via 16S rRNA gene sequencing and LC/MS-based metabolomics. PHYTOMEDICINE : INTERNATIONAL JOURNAL OF PHYTOTHERAPY AND PHYTOPHARMACOLOGY 2022; 101:154107. [PMID: 35561503 DOI: 10.1016/j.phymed.2022.154107] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/24/2021] [Revised: 03/31/2022] [Accepted: 04/14/2022] [Indexed: 06/15/2023]
Abstract
BACKGROUND Cisplatin (CDDP), one of the widely used chemotherapeutic drugs, can induce a series of side effects, such as hepatotoxicity and gastrointestinal toxicity. Astragali Radix (AR) is widely used as the tonic herbal medicine in traditional Chinese medicine (TCM). However, there was no report about the hepatoprotective effect of AR against the cisplatin-induced hepatic damage. PURPOSE This study aimed to investigate the protective effect and potential mechanism of AR water extract against the cisplatin-induced liver injury. METHODS Cisplatin was utilized to induce the liver injury using ICR mice, and the protective effect of AR was evaluated by serum biochemistry indices and liver histopathology. Then UHPLC Q-TOF-MS/MS-based untargeted serum metabolomics approach combined with 16S rRNA-based microbiota analysis was used to explore the underlying biomarkers and mechanism about the liver-protective effect of AR. RESULTS AR could decrease the serum AST and ALT, ameliorate hepatic pathological damages caused by cisplatin. Serum metabolomics indicated AR could regulate the biosynthesis of unsaturated fatty acids, arachidonic acid metabolism, purine metabolism, and fatty acid biosynthesis. In addition, 16S rRNA gene sequencing analysis showed that AR could regulate cisplatin-induced gut microbiota disorder, especially the inflammation-related bacteria (p_Deferribacteres, g_Enterococcus, and g_Alistipes, etc.), and the short chain fatty acids (SCFAs)-producing bacteria (g_Alloprevotella, g_Intestinimoas, and g_Flavonifractor). Moreover, 7 mice (AR-7) showed better liver protective effect than the other 3 mice (AR-3), and their regulatory effect on the gut microbiota and serum metabolites were also different, indicating the presence of inter-individual variability for the liver protective effect of AR. CONCLUSIONS This study revealed the protective effect and the potential mechanisms of AR against cisplatin-induced liver injury, and found that inter-individual variability of the liver protective effect of AR was related to the host microbiome and metabolome. These findings provided new insight into the health effect of dietary AR as a functional food for cisplatin-based chemotherapy.
Collapse
Affiliation(s)
- Ling Wang
- Modern Research Center for Traditional Chinese Medicine, the Key Laboratory of Chemical Biology and Molecular Engineering of Ministry of Education, Shanxi University, No.92, Wucheng Road, Taiyuan, Shanxi 030006, China
| | - Xian-Long Dong
- Modern Research Center for Traditional Chinese Medicine, the Key Laboratory of Chemical Biology and Molecular Engineering of Ministry of Education, Shanxi University, No.92, Wucheng Road, Taiyuan, Shanxi 030006, China
| | - Xue-Mei Qin
- Modern Research Center for Traditional Chinese Medicine, the Key Laboratory of Chemical Biology and Molecular Engineering of Ministry of Education, Shanxi University, No.92, Wucheng Road, Taiyuan, Shanxi 030006, China
| | - Zhen-Yu Li
- Modern Research Center for Traditional Chinese Medicine, the Key Laboratory of Chemical Biology and Molecular Engineering of Ministry of Education, Shanxi University, No.92, Wucheng Road, Taiyuan, Shanxi 030006, China.
| |
Collapse
|
11
|
Hassan NE, El-Masry SA, Nageeb A, El Hussieny MS, Khalil A, Aly MM, Soliman MAT, Ismail A, El-Saeed G, Hashish A, Selim M. Correlation between Gut Microbiota, its Metabolic Products, and their Association with Liver Enzymes among Sample of Egyptian Females. Open Access Maced J Med Sci 2021. [DOI: 10.3889/oamjms.2022.7909] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
Background and Aim: The gut microbiota appears to play a critical role in the pathogenesis of obesity, liver metabolism and the associated diseases. The present study aimed to identify the existing gut microbiota enterotypes and its metabolic products profiles among a sample of normal weight and obese Egyptian females, and to investigate the correlation between gut microbiota; body mass index andliver enzymes among them.Methods: A case-control cross-sectional study, included 112 Egyptian females; 82obese and30 normal weight; with age ranged from 25 up to 60 years. For each participant, anthropometric measurements (weight, height and BMI), laboratory investigations (AST, ALT, SCFA, CRP) and microbiota analysis were done. Results: The obese females had higher significant values of CRP,AST, ALTand SCFA. In addition, obese females had insignificant higher values of log Bacteroidetes, log firmicutes, log firmicutes/ Bacteroidetes ratio, and log lactobacillus, and insignificant lower values of log bifidobacteria; than normal weight group.Among normal weight group, Lactobacillus shad significant positive correlations with SCFA, Bifidobacteria and Firmicutes, and significant negative correlations with AST, ALTand CRP. Bifidobacteria had significant negative correlations with Ht and ALT. Bacteroidetes bacteria had significant positive correlations with SCFA, and significant negative correlations with age and height. Firmicutes bacteria had significant negative correlations with AST and ALT. Firmicutes / Bacteroidetes Ratio had significant negative correlations with AST, ALTand SCFA. Among obese group, Lactobacillus and Bifidobacteria had significant negative correlations with Firmicutes / Bacteroidetes Ratio however; these correlations were insignificant among normal weight group. Moreover, there were insignificant correlations between any type of studied microbiota and any of the anthropometric or laboratory parameters; except Firmicutes bacteria had significant negative correlations with ALT.Conclusion: The beneficial Lactobacillus and bifidobacteria have its good impact in improving obesity status, liver function in form of ALT.
Collapse
|
12
|
Gut Microbiota as the Link between Elevated BCAA Serum Levels and Insulin Resistance. Biomolecules 2021; 11:biom11101414. [PMID: 34680047 PMCID: PMC8533624 DOI: 10.3390/biom11101414] [Citation(s) in RCA: 51] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2021] [Revised: 09/21/2021] [Accepted: 09/23/2021] [Indexed: 12/17/2022] Open
Abstract
The microbiota-harboring human gut is an exquisitely active ecosystem that has evolved in a constant symbiosis with the human host. It produces numerous compounds depending on its metabolic capacity and substrates availability. Diet is the major source of the substrates that are metabolized to end-products, further serving as signal molecules in the microbiota-host cross-talk. Among these signal molecules, branched-chain amino acids (BCAAs) has gained significant scientific attention. BCAAs are abundant in animal-based dietary sources; they are both produced and degraded by gut microbiota and the host circulating levels are associated with the risk of type 2 diabetes. This review aims to summarize the current knowledge on the complex relationship between gut microbiota and its functional capacity to handle BCAAs as well as the host BCAA metabolism in insulin resistance development. Targeting gut microbiota BCAA metabolism with a dietary modulation could represent a promising approach in the prevention and treatment of insulin resistance related states, such as obesity and diabetes.
Collapse
|
13
|
Xu J, Zhan Q, Fan Y, Lo EKK, Zhang F, Yu Y, El-Nezami H, Zeng Z. Clinical Aspects of Gut Microbiota in Hepatocellular Carcinoma Management. Pathogens 2021; 10:pathogens10070782. [PMID: 34206200 PMCID: PMC8308793 DOI: 10.3390/pathogens10070782] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2021] [Revised: 06/13/2021] [Accepted: 06/18/2021] [Indexed: 01/02/2023] Open
Abstract
Liver cancer, predominantly hepatocellular carcinoma (HCC), is the third leading cause of cancer-related deaths worldwide. Emerging data highlight the importance of gut homeostasis in the pathogenesis of HCC. Clinical and translational studies revealed the patterns of dysbiosis in HCC patients and their potential role for HCC diagnosis. Research on underlying mechanisms of dysbiosis in HCC development pointed out the direction for improving the treatment and prevention. Despite missing clinical studies, animal models showed that modulation of the gut microbiota by probiotics may become a new way to treat or prevent HCC development.
Collapse
Affiliation(s)
- Jinghang Xu
- Department of Infectious Diseases, Peking University First Hospital, Peking University, Beijing 100034, China; (J.X.); (Q.Z.); (Y.F.); (Y.Y.)
| | - Qiao Zhan
- Department of Infectious Diseases, Peking University First Hospital, Peking University, Beijing 100034, China; (J.X.); (Q.Z.); (Y.F.); (Y.Y.)
| | - Yanan Fan
- Department of Infectious Diseases, Peking University First Hospital, Peking University, Beijing 100034, China; (J.X.); (Q.Z.); (Y.F.); (Y.Y.)
| | - Emily Kwun Kwan Lo
- School of Biological Sciences, University of Hong Kong, Pokfulam 999077, Hong Kong, China; (E.K.K.L.); (F.Z.)
| | - Fangfei Zhang
- School of Biological Sciences, University of Hong Kong, Pokfulam 999077, Hong Kong, China; (E.K.K.L.); (F.Z.)
| | - Yanyan Yu
- Department of Infectious Diseases, Peking University First Hospital, Peking University, Beijing 100034, China; (J.X.); (Q.Z.); (Y.F.); (Y.Y.)
| | - Hani El-Nezami
- School of Biological Sciences, University of Hong Kong, Pokfulam 999077, Hong Kong, China; (E.K.K.L.); (F.Z.)
- Institute of Public Health and Clinical Nutrition, School of Medicine, University of Eastern Finland, FI-70211 Kuopio, Finland
- Correspondence: (H.E.-N.); (Z.Z.)
| | - Zheng Zeng
- Department of Infectious Diseases, Peking University First Hospital, Peking University, Beijing 100034, China; (J.X.); (Q.Z.); (Y.F.); (Y.Y.)
- Correspondence: (H.E.-N.); (Z.Z.)
| |
Collapse
|